Level 1 — Absolute Beginner

Dr. Marty Makary is the head of the FDA. The FDA is a big food and drug agency. Makary said he will leave his job. The news came on May 12, 2026.

President Trump wrote a message on the internet. He thanked Makary for his work. The president picked a new person. Kyle Diamantas will lead the FDA for now.

Makary had a hard year. Drug companies were not happy with him. Some doctors were also angry. Now the FDA needs a new boss.

FDA

an agency that checks food and drugs in America

resign

to leave a job by choice

agency

a part of the government

chief

the top boss

drug

a medicine

regulator

a person who makes rules

acting

doing a job for a short time

company

a business

Level 2 — Elementary

Dr. Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday, May 12, 2026. He had been in the role for only 13 months. The FDA controls food safety, medicines, and many medical products in the United States.

His time as chief was full of problems. He turned down some new drugs that companies expected to approve. He fought with lawmakers, drugmakers, and even the White House. Patient groups also criticized some of his decisions.

President Donald Trump announced the change on his social media account. He said Kyle Diamantas, who was running the FDA's food office, would take over as acting commissioner. The president will choose a permanent leader later.

commissioner

the leader of a government agency

tumultuous

full of trouble and noise

approval

official permission to do something

lawmaker

a member of Congress who makes laws

criticize

to say something is bad

social media

websites where people share posts

permanent

lasting forever, not just for a short time

office

a part of a company or agency with a job to do

Level 3 — Intermediate

Marty Makary's resignation on May 12, 2026, brings to a close a turbulent 13-month tenure at the head of the U.S. Food and Drug Administration. The Johns Hopkins surgeon, who entered office with a reputation for challenging medical orthodoxy, leaves behind an agency that allies say was reshaped but that critics describe as destabilized.

During his time in office, Makary surprised observers with several high-profile drug rejections, frustrating pharmaceutical executives who had expected smoother approvals. He also clashed publicly with members of Congress and faced mounting pressure from anti-abortion activists who demanded a stricter line on the abortion pill mifepristone.

President Trump announced the departure on Truth Social, thanking Makary for his service and naming Kyle Diamantas, the FDA's top food official, as acting commissioner. Diamantas inherits an agency battered by staff resignations, internal disputes, and an unusually public confrontation between the White House and major drug companies.

Analysts say the next permanent commissioner will face urgent challenges: rebuilding trust with industry, restoring staff morale, and clarifying the agency's stance on contested issues from gene therapies to weight-loss drugs to the broader role of artificial intelligence in drug review.

turbulent

full of conflict and instability

orthodoxy

the standard, accepted view in a field

destabilize

to make something less steady or secure

rejection

a refusal to accept or approve

pharmaceutical

related to the drug industry

mifepristone

a medication used to end early pregnancy

morale

the level of confidence and motivation in a group

stance

an official position on an issue

Level 4 — Advanced

The abrupt resignation of Dr. Marty Makary as commissioner of the Food and Drug Administration on May 12, 2026, closes one of the most contentious chapters in the regulator's recent history. A Johns Hopkins surgeon and longtime critic of medical groupthink, Makary entered office promising structural reform; he departs amid a chorus of complaints from drugmakers, congressional staff, patient advocates, and senior career officials who say the agency has grown both ideologically erratic and operationally brittle.

His thirteen-month tenure was punctuated by unexpected drug rejections, internecine battles over the abortion pill mifepristone, and a string of high-profile resignations among scientific reviewers. Pharmaceutical executives, accustomed to predictable timelines and well-trodden approval pathways, found themselves navigating decisions that they argued reflected the commissioner's personal convictions more than agency precedent. Anti-abortion activists, meanwhile, accused him of insufficient vigilance, while reproductive-rights groups warned that any tightening of the rules would imperil access nationwide.

President Trump's announcement, delivered via Truth Social, named Kyle Diamantas — the agency's senior food regulator — as acting commissioner. Diamantas inherits an FDA whose institutional credibility has been eroded on multiple fronts: a workforce demoralized by departures and reorganizations, an industry skeptical of regulatory predictability, and a White House that has, on more than one occasion, publicly second-guessed its own appointees. The pending nomination of a permanent successor will be closely watched as a signal of whether the administration intends to consolidate Makary's heterodox approach or to course-correct toward the more conventional posture favored by industry and many career staff.

Beyond personnel, the deeper question is whether the FDA can re-anchor its scientific authority at a moment when artificial intelligence is reshaping drug discovery, biosimilars are testing the boundaries of generic approval, and weight-loss and gene therapies are dominating both clinics and stock tickers. The next commissioner, whoever the White House selects, will need to do more than steady the agency; they will need to articulate a coherent regulatory philosophy for a biomedical landscape that is changing faster than any previous generation of regulators has had to manage.

groupthink

uncritical agreement within a group that leads to poor decisions

internecine

destructive conflict within a group

precedent

an earlier action used as a guide for similar later ones

credibility

the quality of being trusted or believed in

demoralized

having lost confidence, motivation, or hope

heterodox

not in agreement with accepted beliefs or standards